Mechanism of Action

BAXDELA^® (delafloxacin) Mechanism of Action

MOLECULAR ENGINEERING HAS LED TO THE CREATION OF BAXDELA

• Anionic in nature
• Antibacterial activity is due to the inhibition of topoisomerase IV and DNA gyrase
  • Similar affinity for both enzymes^1,2
• Complex pathway required for resistance
  • In vitro resistance to BAXDELA developed by multiple step mutations in the quinolone-resistance determining regions of gram-positive and gram-negative bacteria. BAXDELA-resistant mutants were selected in vitro at a frequency of <10^-9
• Cross-resistance between BAXDELA and other fluoroquinolones has been observed. However, some isolates resistant to other fluoroquinolones may be susceptible to BAXDELA

1. Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10(7):1111-1123. doi:10.2217/fmb.15.39
2. Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7(2):197-217. doi:10.1007/s40121‑018‑0198‑x